Search
STI-1499
go.drugbank.com/drugs/DB16487InvestigationalSTI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.
Becatecarin
go.drugbank.com/drugs/DB06362InvestigationalBecatecarin is a derivative of [rebeccamycin].
Lancovutide
go.drugbank.com/drugs/DB05029InvestigationalLantibiotics are bacteriocins that are characterized by the presence of a high proportion of unusual amino acids. … Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis.
Sifalimumab
go.drugbank.com/drugs/DB12773InvestigationalSifalimumab is a fully human monoclonal antibody targeting interferon-alpha. … The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity.
Zeatin
go.drugbank.com/drugs/DB11337InvestigationalAn aminopurine factor in plant extracts that induces cell division. (Grant & Hackh's Chemical Dict, 5th ed)
Synonyms: (E)-2-methyl-4-(1H-purin-6-ylamino)-2-buten-1-ol, (E)-2-methyl-4-(purin-6-ylamino)-2-buten-1-olCadisegliatin
go.drugbank.com/drugs/DB18886InvestigationalCadisegliatin is under investigation in clinical trial NCT06334133 (Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes).
MCMV5322A
go.drugbank.com/drugs/DB17763InvestigationalMCMV5322A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV3068A] to form RG7667.[A259362]
MCMV3068A
go.drugbank.com/drugs/DB17764InvestigationalMCMV3068A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV5322A] to form RG7667.[A259362]
CTX130
go.drugbank.com/drugs/DB18627InvestigationalCTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
PLX51107
go.drugbank.com/drugs/DB17543InvestigationalPLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family. … [A257246,A257251] PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome).